Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the ...

Buyout firm Advent International is considering the sale of generic drugmaker Zentiva, in a deal that could value the former Sanofi unit at about €5 billion ($5.4 billion), according to people ...

The UWWTD will require manufacturers to fund micropollutant removal, but Zentiva says the financial squeeze could mean ...

Directive Might Cause Massive Medicine Shortages Affecting Millions Of Patients Across Europe ...